ADC Therapeutics SA (ADCT) – Hot FDA News
-
ADC Therapeutics SA (ADCT) to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
-
ADC Therapeutics SA (ADCT) Announces Voluntary Pause of Enrollment in Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
-
Back to ADCT Stock Lookup